Myasthenia Gravis Comprehensive Study Notes
Overview of Myasthenia Gravis (MG)
- Definition and Origin
* Myasthenia Gravis is a chronic autoimmune neuromuscular disease.
* Etymology: The name is derived from Latin and Greek meaning ‐grave muscle weakness.‐
* Core characteristic: Muscle weakness that increases with physical activity and improves after periods of rest.
* Primary site of dysfunction: A disorder at the neuron junction that interferes with the transmission of Acetylcholine (ACH).
Anatomic Alterations and Pathophysiology
- Mechanical Interference
* MG involves the neuromuscular junction, specifically interfering with the transmission of ACH between the axonal terminal and the receptor sites of voluntary muscles.
* The body produces its own antibodies (specifically IgG antibodies) that block the ACH receptor sites. - Mechanism of Chemical Transmission Disruption
* The antibodies block ACH from reaching the receptor sites of the muscular cell.
* The antibodies accelerate the breakdown of ACH.
* The antibodies destroy the receptor sites entirely. - Secondary Anatomic Alterations of the Lungs
* If ventilatory failure is not properly managed, the following can occur:
* Mucous accumulation
* Airway obstruction
* Alveolar consolidation
* Atelectasis (a common secondary anatomic alteration) - Targeted Muscle Groups
* The disease mainly affects voluntary muscles, including:
* Eyelids and eyes.
* Facial movement (chewing and talking).
* Muscles controlling breathing.
* Neck and limb muscles.
* In severe cases, diaphragmatic paralysis and ventilatory failure may develop.
Etiology and Demographics
- Prevalence
* In the United States, there are approximately 20 people with Myasthenia Gravis for every 100,000 people. - Demographics
* Most common in young women: Usually under the age of 40 (specifically between ages 15 to 35).
* Most common in older men: Usually over the age of 60 (specifically between ages 40 to 70). - Provoking Factors for Clinical Manifestations
* Emotional upset
* Physical stress
* Exposure to extreme temperature changes
* Febrile illness
* Pregnancy
Diagnosis and Testing
- Diagnostic Modalities
* Clinical history of weakness in specific areas and decreased strength throughout the day.
* Neurologic examination.
* Electromyography (EMG).
* Blood analysis (searching for ACH receptor antibodies).
* Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). - Ice Pack Test
* Used specifically for patients with ptosis (droopy eye).
* Involves the application of an ice pack for 5 minutes to observe improvement in eyelid drooping. - Edrophonium (Tensilon) Challenge
* Used to diagnose MG and monitor drug therapy levels.
* Case 1: Improvement (Myasthenic Crisis)
* If symptoms improve with Tensilon, it is referred to as a Myasthenic Crisis.
* Indicates a need for more anticholinesterase drug therapy.
* Maintenance drugs: Neostigmine (Prostigmin) and Pyridostigmine (Mestinon, Regonol).
* Case 2: Worsened Symptoms (Cholinergic Crisis)
* If symptoms worsen with Tensilon, it is referred to as a Cholinergic Crisis.
* Indicates that too much medication has been administered.
* Treatment: Administer Atropine to reverse the effects of Tensilon and relieve symptoms of the cholinergic crisis.
Clinical History and Physical Examination
- Hallmark Symptoms
* Chronic muscle fatigue.
* Facial muscle weakness.
* Ptosis: Drooping of one or both eyelids.
* Diplopia: Double vision.
* Dysphagia: Difficulty swallowing.
* Difficulty speaking, chewing, and breathing.
* Unstable gait.
* Weakness in arms, hands, fingers, legs, and neck, especially after repetitive motions. - Respiratory Impact
* Muscles of the diaphragm and chest wall can weaken, impairing ventilation.
* Impairment of deep breathing and coughing predisposes the patient to excessive bronchial secretions, pneumonia, and atelectasis. - Physical Exam Findings
* General weakness: Often described as ‐mind to ground.‐
* Respiratory rate: Varies based on the degree of muscle paralysis; may lead to apnea in severe cases.
* Cyanosis.
* Decreasing VT, VC, and MIP.
* Chest assessment: Diminished breath sounds, crackles, and rhonchi.
Cardiopulmonary and Laboratory Findings
- Pulmonary Function Test (PFT)
* Pattern: Moderate to Severe Restrictive Lung Pathophysiology.
* Measured values (all decreased):
* Tidal Volume (VT): Decreased
* Inspiratory Reserve Volume (IRV): Decreased
* Expiratory Reserve Volume (ERV): Decreased
* Residual Volume (RV): Decreased
* Vital Capacity (VC): Decreased
* Inspiratory Capacity (IC): Decreased
* Functional Residual Capacity (FRC): Decreased
* Total Lung Capacity (TLC): Decreased
* RV/TLC ratio: Normal.
* Negative Inspiratory Pressure (NIP) / Force: Decreased. - Arterial Blood Gases (ABG)
* Indicates Acute Ventilatory Failure with Hypoxemia (Acute Respiratory Acidosis) in moderate to severe cases.
* pH: Decreased.
* PaCO2: Increased.
* HCO3: Slightly increased.
* PaO2: Decreased. - Radiologic Findings
* Early stage: Typically normal.
* Advanced stage: Increased opacity when atelectasis is present.
General Management and Therapeutic Protocols
- Monitoring
* Frequent measurements required: VC, NIF, Blood Pressure, Pulse Oximetry (SpO2), and ABG. - Respiratory Care Protocols
* Oxygen Therapy: Increase FiO2 up to 60%. If higher support is needed, add CPAP/PEEP.
* Hyperinflation Therapy: Example: IPPB (Intermittent Positive Pressure Breathing) used for atelectasis.
* Airway Management: Bronchopulmonary Hygiene and Lung Expansion Therapy protocols to prevent mucus accumulation.
* Mechanical Ventilation: Initiated when clinical data demonstrate impending or acute ventilatory failure. - Indicators for Acute Ventilatory Failure
* Vital Capacity (VC) < 20mL/kg.
* Negative Inspiratory Force (NIF) < −30cmH2O.
* pH < 7.35 or PaCO2 > 45mmHg. - Medical and Surgical Treatments
* Historical note: First attempt to treat MG recorded on June 2nd, 1935.
* Cholinesterase inhibitors.
* Immunosuppressants.
* Adrenocorticotropic hormone therapy.
* Thymectomy: Removal of the thymus gland (questioned whether this is a cure or just stops progression).
* Plasmapheresis.
Questions and Discussion
- Anatomic Site of Problem: The fundamental anatomic alteration in MG is a problem with voluntary muscle acetylcholine (ACH) transmission.
- Pathologic Mechanism: IgG (not IgE) antibodies cause weakness by blocking ACH sites, destroying sites, or accelerating ACH breakdown; they do not break down the nerves' myelin sheath.
- Major Lung Changes: The major pathologic changes associated with ventilatory failure in MG are alveolar consolidation and atelectasis.
- Chest Assessment Findings: Common findings include diminished breath sounds, crackles, and rhonchi.
- Most Important Assessment for Ventilatory Failure: Negative Inspiratory Force (NIF) is critical for determining acute ventilatory failure peaks.